Parkinson’s disease: towards better preclinical models and personalized treatments (original) (raw)

The review discusses the limitations of current preclinical models of Parkinson's disease (PD) and highlights the importance of better understanding the pathogenic mechanisms involved in the disease. It emphasizes the need for novel biomarkers and improved preclinical models to facilitate the development of individualized, effective treatments. The authors stress that while neurotrophic factors show promise, modest clinical results indicate a need for further research into their efficacy and delivery methods.